Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gender difference in ranolazine pharmacokinetics in rats.

Literature DB >> 12877569

Gender difference in ranolazine pharmacokinetics in rats.

Abstract

Pharmacokinetics of ranolazine (RAN) in both female and male rats was studied. RAN concentrations in plasma were determined after oral administration of 12.5, 25 and 50 mg/kg RAN. Concentrations in tissues, recoveries of RAN in urine and bile were also analyzed following oral dose of 25 mg/kg. It was found that plasma concentrations of RAN in female rats were significantly higher than those in male rats. Drug exposures based on Cmax and AUC in female rats were roughly 2-to 3-fold of those in male rats. Terminate half-life T1/2 and MRT in male rats were shorter than those in female rats. The recoveries in urine and bile of female rats were also markedly higher than those in male rats'. Tissue concentrations of RAN in female rats were also markedly higher than those in male rats. These results demonstrated existence of marked gender difference in RAN pharmacokinetics in rats.

Entities: Chemical Species

Mesh：

Substances：

Year: 2003 PMID： 12877569 DOI： 10.1007/BF03190499

Source DB: PubMed Journal: Eur J Drug Metab Pharmacokinet ISSN： 0378-7966 Impact factor: 2.441

8 in total

1. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease.

Authors: J P Bagger; H E Bøtker; A Thomassen; T T Nielsen
Journal: Cardiovasc Drugs Ther Date: 1997-07 Impact factor: 3.727

2. Antianginal effects of ranolazine in various experimental models of angina.

Authors: J X Wang; K Maruyama; M Murakami; T Endo; H Komatsu; M Akahane
Journal: Arzneimittelforschung Date: 1999-03

3. Estimation of ranolazine and eleven phase I metabolites in human plasma by liquid chromatography-atmospheric pressure chemical ionisation mass spectrometry with selected-ion monitoring.

Authors: W J Herron; J Eadie; A D Penman
Journal: J Chromatogr A Date: 1995-09-29 Impact factor: 4.759

4. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.

Authors: C J Pepine; A A Wolff
Journal: Am J Cardiol Date: 1999-07-01 Impact factor: 2.778

5. Gender difference in letrozole pharmacokinetics in rats.

Authors: X D Liu; L Xie; Y Zhong; C X Li
Journal: Acta Pharmacol Sin Date: 2000-08 Impact factor: 6.150

6. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

Authors: J C Gorski; D R Jones; B D Haehner-Daniels; M A Hamman; E M O'Mara; S D Hall
Journal: Clin Pharmacol Ther Date: 1998-08 Impact factor: 6.875

7. Gender differences in toxicokinetics, liver metabolism, and plasma esterase activity: observations from a chronic (27-week) toxicity study of enalapril/diltiazem combinations in rats.

Authors: L E Los; D A Welsh; E G Herold; W J Bagdon; A G Zacchei
Journal: Drug Metab Dispos Date: 1996-01 Impact factor: 3.922

8. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.

Authors: J G McCormack; R L Barr; A A Wolff; G D Lopaschuk
Journal: Circulation Date: 1996-01-01 Impact factor: 29.690